|
| << previous | next >> |
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
Details for article 32 of 52 found articles
| Title: |
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial |
| Author: |
Xu, Rui-Hua Muro, Kei Morita, Satoshi Iwasa, Satoru Han, Sae Won Wang, Wei Kotaka, Masahito Nakamura, Masato Ahn, Joong Bae Deng, Yan-Hong Kato, Takeshi Cho, Sang-Hee Ba, Yi Matsuoka, Hiroshi Lee, Keun-Wook Zhang, Tao Yamada, Yasuhide Sakamoto, Junichi Park, Young Suk Kim, Tae Won |
| Appeared in: |
Lancet oncology |
| Paging: | Volume 19 (2018) nr. 5 pages 660-671 |
| Year: |
2018 |
| Contents: | |
| Publisher: |
Elsevier Ltd |
| Source file: |
Elektronische Wetenschappelijke Tijdschriften |
Details for article 32 of 52 found articles
| << previous | next >> |